Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the overcast skies hovering above the Pharmalot campus. Our official mascot is curled up nearby and snoozing happily. And the coffee kettle is whistling once again in preparation for another delicious cup of stimulation. In other words, the proverbial coffee cup is half full. Better than half empty, yes? On that note, it is time, once again, to get cracking. Here are a few tidbits to help you on your journey. Hope today goes well, and do keep in touch. …

Shenzhen Kangtai Biological Products will produce a Covid-19 vaccine in mainland China that is being developed by AstraZeneca (AZN), its first deal to supply one of the world’s most populous countries, Reuters notes. The deal underscores a global race to deliver an effective vaccine, given that Chinese ventures are leading at least eight of the 26 global vaccine development projects currently testing in humans. Under the deal, Shenzhen Kangtai will ensure it has annual production capacity of at least 100 million doses of the experimental shot.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy